Diabetes 

Diabetes affects more than 10% of the U.S. population. Every day, new research adds to our understanding of this disease’s complex typology, epidemiology, pathophysiology, and associated comorbidities. In recent years, the range and number of drugs and devices available to manage type 2 and type 1 diabetes has increased dramatically. This has been accompanied by new clinical research and major updates to treatment guidelines.

The most effective diabetes writing takes this rapidly evolving clinical landscape into account. MedLitera specializes in diabetes communications.

• We have a first-hand understanding of key scientific and policy developments from the past 20 years.

• We keep an eye on new treatments and key clinical studies.

• We know the disease’s history—the major clinical trials that have been conducted, and their impact on treatment patterns over time.

• We work closely with and understand the concerns of endocrinologists, primary care clinicians, and other healthcare providers.

Recent diabetes-related projects that MedLitera has worked on include:

• Advisory board coverage

• Continuing medical education assessments and content

• Clinical Guidelines and Consensus Statements

• Health economics analyses

• Literature for patients

• Posters and abstracts

• Peer-reviewed publications (original research, literature reviews)

• Slide kits

• Systematic literature reviews

• White papers

See published documents with medical writing provided by MedLitera.